LV12271B - COMBINED VACCINE FOR CHILDREN WITH HIGHLY VACCINE COMPONENT IMUNOGENIC ACTIVITY - Google Patents

COMBINED VACCINE FOR CHILDREN WITH HIGHLY VACCINE COMPONENT IMUNOGENIC ACTIVITY Download PDF

Info

Publication number
LV12271B
LV12271B LVP-99-29A LV990029A LV12271B LV 12271 B LV12271 B LV 12271B LV 990029 A LV990029 A LV 990029A LV 12271 B LV12271 B LV 12271B
Authority
LV
Latvia
Prior art keywords
vaccine
antigen
diphtheria
tetanus
pertussis
Prior art date
Application number
LVP-99-29A
Other languages
English (en)
Latvian (lv)
Other versions
LV12271A (lv
Inventor
Peter R. Paradiso
Deborah A. Hogerman
Dace Viceps Madore
Jill G. Hackell
Original Assignee
American Cyanamid Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Company filed Critical American Cyanamid Company
Publication of LV12271A publication Critical patent/LV12271A/xx
Publication of LV12271B publication Critical patent/LV12271B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Peptides Or Proteins (AREA)
LVP-99-29A 1992-10-27 1999-02-22 COMBINED VACCINE FOR CHILDREN WITH HIGHLY VACCINE COMPONENT IMUNOGENIC ACTIVITY LV12271B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96699592A 1992-10-27 1992-10-27

Publications (2)

Publication Number Publication Date
LV12271A LV12271A (lv) 1999-05-20
LV12271B true LV12271B (en) 1999-07-20

Family

ID=25512167

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-99-29A LV12271B (en) 1992-10-27 1999-02-22 COMBINED VACCINE FOR CHILDREN WITH HIGHLY VACCINE COMPONENT IMUNOGENIC ACTIVITY

Country Status (23)

Country Link
EP (1) EP0594950B1 (no)
JP (1) JPH07300427A (no)
KR (1) KR100289224B1 (no)
AT (1) ATE176157T1 (no)
AU (1) AU669570B2 (no)
CA (1) CA2109159A1 (no)
CZ (1) CZ283587B6 (no)
DE (2) DE69323264D1 (no)
DK (1) DK0594950T3 (no)
ES (1) ES2126616T3 (no)
FI (1) FI934725A (no)
GR (1) GR3029884T3 (no)
HK (1) HK1009931A1 (no)
HU (1) HU215149B (no)
IL (1) IL107387A (no)
LV (1) LV12271B (no)
NO (1) NO308588B1 (no)
NZ (1) NZ250029A (no)
PL (1) PL174130B1 (no)
RU (1) RU2121365C1 (no)
SG (1) SG47725A1 (no)
TW (1) TW256774B (no)
UA (1) UA27754C2 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1864195A (en) * 1994-03-07 1995-09-25 Auckland Uniservices Limited Prevention of diabetes
JP4233113B2 (ja) * 1995-06-07 2009-03-04 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
ES2157447T5 (es) * 1995-06-23 2011-04-29 Smithkline Beecham Biologicals S.A. Una composición de vacuna que comprende un antígeno conjugado de polisacárido de haemofilus influenzae tipo b adsorbido en fosfato de aluminio.
BR9710460A (pt) * 1996-07-02 1999-08-17 Connaught Lab Composi-Æo imunolÄgica multi-valente e seu uso em vacinas
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
UA76952C2 (uk) * 2000-06-29 2006-10-16 Глаксосмітклайн Байолоджікалз С.А. Полівалентна імуногенна композиція, спосіб її виготовлення, застосування у виробництві лікарського засобу для лікування або попередження захворювань, викликаних інфекцією haemophilus influenzae типу в та спосіб імунізації людини-хазяїна від захворювання, викликаного haemophilus influenzae типу в
PT2395073T (pt) 2002-11-01 2017-11-24 Glaxosmithkline Biologicals Sa Processo de secagem
GB0505996D0 (en) * 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates

Also Published As

Publication number Publication date
TW256774B (no) 1995-09-11
DK0594950T3 (da) 1999-09-13
CA2109159A1 (en) 1994-04-28
NO933856L (no) 1994-04-28
AU5029093A (en) 1994-05-12
GR3029884T3 (en) 1999-07-30
FI934725A0 (fi) 1993-10-26
HU215149B (hu) 2000-03-28
DE69323264D1 (de) 1999-03-11
EP0594950B1 (en) 1999-01-27
IL107387A0 (en) 1994-01-25
RU2121365C1 (ru) 1998-11-10
LV12271A (lv) 1999-05-20
HUT67239A (en) 1995-03-28
PL174130B1 (pl) 1998-06-30
SG47725A1 (en) 1998-04-17
CZ227293A3 (en) 1994-05-18
FI934725A (fi) 1994-04-28
AU669570B2 (en) 1996-06-13
KR940008698A (ko) 1994-05-16
UA27754C2 (uk) 2000-10-16
EP0594950A1 (en) 1994-05-04
ES2126616T3 (es) 1999-04-01
NZ250029A (en) 1994-09-27
KR100289224B1 (ko) 2001-05-02
HU9303028D0 (en) 1994-01-28
NO308588B1 (no) 2000-10-02
ATE176157T1 (de) 1999-02-15
NO933856D0 (no) 1993-10-26
CZ283587B6 (cs) 1998-05-13
DE69323264T4 (de) 1999-10-14
IL107387A (en) 1997-04-15
DE69323264T2 (de) 1999-06-02
JPH07300427A (ja) 1995-11-14
HK1009931A1 (en) 1999-06-11

Similar Documents

Publication Publication Date Title
JP5637848B2 (ja) 髄膜炎ワクチンの製剤化
JP4871770B2 (ja) 組み合わせ髄膜炎ワクチン
US6329512B1 (en) Immunogenic conjugate molecules
RU2444374C2 (ru) Получение вакцин, содержащих поверхностный антиген вируса гепатита в и поверхностно-активное вещество
Weinberg et al. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide—Neisseria meningitidis outer membrane protein conjugate vaccine
RU2420315C2 (ru) Комбинированные вакцины с антигеном коклюша цельных клеток
JP2010529103A5 (no)
SK283565B6 (sk) Multivalentná imunogénna kompozícia a jej použitie
US9040058B2 (en) Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
WO2012093406A2 (en) A combination heptavalent vaccine
Alexander et al. Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE®)
JP2012506420A (ja) 全細胞百日咳を含む混合ワクチン
EP0594950B1 (en) Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
Redhead et al. Combination of DTP and Haemophilus influenzae type b conjugate vaccines can affect laboratory evaluation of potency and immunogenicity
EP2592137A1 (en) Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
AU2013203663B2 (en) Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
Schedule et al. Supplementary Table 1: Trials included in Hib conjugate vaccine review, detailed information
Gross 2 Combination Vaccines
PL174077B1 (pl) Szczepionka do ochrony przed zakażeniem lub leczeniem zakażeń Hepatitis B i heterologicznych chorób, zawierająca antygen powierzchniowy Hepatitis B (HBsAg)
GB2498112A (en) Preparation of a diphtheria toxoid by incubating toxin concentrate with an amino acid and formaldehyde